Ask yourself, who would buy 5 million, or 1 million, or 100k shares being "naked shorted in Europe". Someone who didn't know that this was happening? Someone who didn't want to buy in the OTC at 14, 15, 20 cents, but would buy on a European exchange.
Even at 14 cents, DKAM is valued at over $15 million (fully diluted), or 2.5 to 7 times annual sales. That doesn't sound unreasonably high to me at all, especially when you consider they just paid Olifant 70% of their annual sales over a 4 year period. Personally, I think that one or more stockholders who bought on expectations that the stock would have taken off by now are giving up and putting their shares up for sale at whatever they can get. There are not a lot of buyers these days for any stock, let alone one with the risks of DKAM, so the price is kind of stuck. I would not be surprised if some smaller stockholders and potential investors are waiting to see the results of the last Q, with Israel, Germany and some Leyrat and Olifant. If it's strong, I would expect a modest increase in the PPS. If it's around last Q, or worse, I would look for a further decline. If sales increase somewhat, margins go back to historical levels and net loss is around $1 million for the quarter (my personal guess), I think it will sit in this range for some time.
All MHO.